ISSN 1070-4280, Russian Journal of Organic Chemistry, 2012, Vol. 48, No. 3, pp. 399–410. © Pleiades Publishing, Ltd., 2012. Original Russian Text © V.A. Samsonov, Yu.V. Gatilov, V.A. Savel'ev, S.S. Baranova, 2012, published in Zhurnal Organicheskoi Khimii, 2012, Vol. 48, No. 3, pp. 403–413.

Reactions of 5-Nitrospiro[benzimidazole-2,1'-cyclohexane] 1,3-Dioxide with Nucleophiles

V. A. Samsonov, Yu. V. Gatilov, V. A. Savel'ev, and S. S. Baranova

Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Division, Russian Academy of Sciences, pr. Akademika Lavrent'eva 9, Novosibirsk, 630090 Russia e-mail: Samson@nioch.nsc.ru

Received August 11, 2011

Abstract—Reactions of 5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1,3-dioxide with aliphatic amines and sodium hydroxide resulted in removal of one *N*-oxide oxygen atom and formation of 4-alkylamino- or 4-hydroxy-substituted 5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1-oxides, respectively. The title compound reacted with ammonia and methylamine in the presence of MnO₂ with conservation of both *N*-oxide moieties, and the products were 4-amino- and 4-methylamino-5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1,3-dioxides. The reactions with aromatic amines were accompanied by removal of both *N*-oxide oxygen atoms with formation of *N*-aryl-5-nitrospiro[benzimidazole-2,1'-cyclohexane]-4-amines. In the reactions of 5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1,3-dioxide with sodium azide and aromatic amine hydrochlorides nucleophilic replacement of the 5-nitro group by azido or arylamino occurred, in the first case both *N*-oxide fragments being conserved. The reactions with aromatic amine hydrochlorides afforded *N*-aryl-5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1,3-dioxide with sodium conserved. The reactions with aromatic amine hydrochlorides afforded *N*-aryl-5-nitrospiro[benzimidazole-2,1'-cyclohexane] -4-amine 1-oxides. Treatment of 5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1,3-dioxide with sodium cyanide led to the formation of 5-oxo-3,5-dihydrospiro[benzimidazole-2,1'-cyclohexane]-4-carbonitrile 1-oxide.


DOI: 10.1134/S1070428012030116

2*H*-Benzimidazoles and their derivatives attract researchers' attention as starting compounds for the synthesis of a number of heterocyclic compounds [1, 2]. 2*H*-Benzimidazole 1,3-dioxides have been studied to a considerably lesser extent despite their unusual reactivity [3]. Some 2*H*-benzimidazole 1,3-dioxides showed high biological activity against *Tripa*nosoma cruzi and Leishmania spp. According to the World Health Organization data, these trypanosomatids alone are responsible for an infected population of nearly 30 million and more than 400 million are at risk [4–6]. Therefore, studies on the properties and development of methods of synthesis of 2*H*-benzimidazole-1,3-dioxides and preparation of their new derivatives constitute an important problem.

The main procedure for the synthesis of 2*H*-benzimidazole 1,3-dioxides is based on reaction of benzofuroxans with secondary nitroalkanes in the presence of a base. Nitro derivatives of benzofuroxan failed to react in such a way [3]. We have developed a procedure for the synthesis of 2*H*-benzimidazole 1,3-dioxides via reaction of benzofuroxans with alcohols or haloalkanes in sulfuric or perchloric acid [7]. The procedure ensured preparation of a large series of 2*H*-benzimidazole 1,3-dioxides, including those inaccessible by other methods.


The *ortho*-quinone diimine structure of 2*H*-benzimidazole 1,3-dioxides implies that such compounds should be capable of reacting with nucleophiles to give the corresponding addition products, which is typical of quinoid systems. We previously showed that 4,7-dibromo-2,2-dimethyl-2*H*-benzimidazole 1,3-dioxide takes up amine molecule with simultaneous removal of one *N*-oxide oxygen atom and two hydrogen atoms, the *ortho*-quinone diimine system being retained [8].

In continuation of these studies in the present work we examined reactions of 5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1,3-dioxide (I) prepared by us previously [7] with some nucleophilic reagents. Compound I reacted with ammonia in chloroform to produce amine IIa (Scheme 1). According to the analytical and spectral data, nucleophilic replacement in molecule I was accompanied by elimination of one *N*-oxide oxygen atom and two hydrogen atoms. With a view to



II, $R^1 = R^2 = H$ (a); $R^1 = H$, $R^2 = Me$ (b), HOCH₂CH₂ (c), Me(CH₂)₂ (d), Me(CH₂)₃ (e), *t*-Bu (f), cyclohexyl (g), 2,2,6,6-tetramethyl-piperidin-4-yl (h), PhCH₂ (i), PhCH₂CH₂ (j); $R^1R^2N =$ piperidino (k), morpholino (l), pyrrolidin-1-yl (m); V, R = H (a), Me (b).

elucidate which N-oxide oxygen atom was lost in this reaction, we obtained a single crystal of IIa, and the structure of this compound was unambiguously determined by X-ray analysis (see figure). The benzimidazole fragment in molecule IIa is planar within ± 0.015 Å. The nitro and amino groups reside in the benzimidazole ring plane, the corresponding dihedral angles being equal to 3.19(4) and $1.7(4)^{\circ}$, respectively. The bond lengths in molecule IIa are similar to those found for dispiro[benzimidazole-2,1'-cyclohexane-4'.2"-benzimidazole] 1-oxide and dispiro[benzimidazole-2,1'-cyclohexane-4',2"-benzimidazole] 1,1"-dioxide [9]. Intramolecular hydrogen bonds $N^2-H\cdots O^2$ [N–H 0.86(2), H…O 2.08(2) Å, ∠NHO 123(2)°] and N^2 -H···N³ [0.89(2), 2.40(2) Å, 105(1)°], as well as intermolecular hydrogen bond N^2 -H···O¹ [0.86(2), 2.23(2) Å, $121(2)^{\circ}$], were detected in the crystalline




Structure of the molecule of 5-nitrospiro[benzimidazole-2,1'cyclohexan]-4-amine 1-oxide (IIa) according to the X-ray diffraction data.

structure of compound IIa; the latter bond is responsible for the formation of chains along the *c* axis. Also, intermolecular N⁴–O²··· π interactions were found with the following parameters: O···centroid (C_g) 3.387(1) (benzo), 3.362(1) Å (imidazole), $\angle NOC_g$ 100.81(9), 100.30(9)°.

Treatment of N-oxide IIa in alcohol with aqueous sodium hydroxide gave compound III which was assigned the structure of 5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-ol 1-oxide on the basis of its spectral parameters and elemental analysis. The ¹H NMR spectrum of III contained signals from five CH₂ groups in the cyclohexane ring (δ 1.23–1.98 ppm, m), signals from aromatic protons as two doublets at δ 6.58 and 7.40 ppm, and a singlet at δ 9.45 ppm belonging to the hydroxy proton. In the ¹³C NMR spectrum of III, signals from methylene carbon atoms appeared at $\delta_{\rm C}$ 22.83, 24.21, and 34.34 ppm, two aromatic CH carbon atoms resonated at δ_C 103.90 and 125.52 ppm, and five quaternary carbon atoms gave signals at $\delta_{\rm C}$ 105.80, 133.18, 135.75, 153.24, and 160.21 ppm. Presumably, the position of the N-oxide moiety in molecule III is the same as in IIa. By reaction of compound III with diazomethane we obtained 4-methoxy-5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1-oxide (IV). Compound III was also formed directly from 1,3-dioxide I by the action of aqueous alkali.

Primary and secondary amines readily reacted with compound I to produce mono-*N*-oxides IIb–IIm. The position of the *N*-oxide moiety in the products was the same as in compound IIa. This follows from the



formation of *N*-oxide **III** in the reaction of nitro amines **IIc**, **IIk**, and **III** with aqueous alkali as a result of replacement of the amino group by hydroxy. Compound **III** thus obtained was identified by comparing the IR spectra and melting points. Amines **IIc**, **IIk**, and **III** were also synthesized by reaction of 5-nitrospiro-[benzimidazole-2,1'-cyclohexane] 1-oxide (**VI**) reported by us previously [11] with 2-aminoethanol, piperidine, and morpholine, respectively (Scheme 2). Alkylation of **IIa** with methyl iodide gave compound **IIb**. The above findings allowed us to presume the same position of the *N*-oxide oxygen atom in all compounds **IIa–IIm**.

5-Nitrospiro[benzimidazole-2,1'-cyclohexan]-4amine 1,3-dioxide (Va) was synthesized by reaction of compound I with ammonia in the presence of MnO_2 as oxidant. Presumably, the reaction involves initial nucleophilic 1,6-addition of ammonia to molecule I with formation of adduct A which is oxidized with MnO₂ to give Va. The structure of 5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-amine 1,3-dioxide (Va) was determined on the basis of its spectral parameters and elemental composition (see Experimental). Protons in the amino group resonated in the ¹H NMR spectrum of Va as two singlets at δ 8.75 and 9.22 ppm, presumably due to formation of intramolecular hydrogen bond between the N-oxide oxygen atom and hydrogen atom in the amino group, as well as between the nitro group and the other amino hydrogen atom. Likewise, in the reaction of I with MeNH₂ in the presence of MnO₂ both N-oxide groups were conserved, and the product was N-methyl-5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-amine 1,3-dioxide (Vb) (Scheme 1).

The reactions of compound I with aromatic amines were accompanied by loss of both *N*-oxide oxygen atoms with formation of *N*-arylspiro[benzimidazole-2,1'-cyclohexan]-4-amines **VIIa–VIIf** (Scheme 3). These reactions were carried out by prolonged heating of a mixture of I and aromatic amine in boiling benzene or alcohol. Presumably, initial elimination of *N*-oxide oxygen atoms from molecule I gives the corresponding 2*H*-benzimidazole which then reacts with aromatic amine. As shown by us previously [10], compound **I** is a strong oxidant, and it loses *N*-oxide oxygen atoms on heating. This is likely to be responsible for the formation of a considerable amount of tars in the reaction of **I** with aromatic amines.


The reaction of **I** with sodium azide occurred as nucleophilic replacement of the nitro group by azido with conservation of the *N*-oxide groups and formation of 5-azidospiro[benzimidazole-2,1'-cyclohexane] 1,3-dioxide (**VIII**) (Scheme 3). The IR spectrum of **VIII** contained an absorption band at 2117 cm⁻¹, which is typical of stretching vibrations of azido group. The other analytical and spectral parameters of **VIII** were also consistent with the assumed structure (see Experimental).

Compound I reacted with aromatic amine hydrochlorides (aniline, 4-methoxyaniline, and 3-nitroaniline hydrochlorides) to give the corresponding *N*-arylspiro-[benzimidazole-2,1'-cyclohexan]-5-amine 1-oxides **IXa–IXc** whose structure was confirmed by spectral and analytical data. The position of the *N*-oxide group was determined taking into account the formation of compound **IXb** in the reaction of **VI** with 3-nitroaniline hydrochloride. It should be noted that the reaction of *N*,*N*'-dioxide **I** with aniline hydrochloride was accompanied by formation of a small amount of *N*-phenylspiro[benzimidazole-2,1'-cyclohexan]-5amine 1,3-dioxide (**IXd**).

The reaction of I with sodium cyanide in methanol afforded 5-methoxyspiro[benzimidazole-2,1'-cyclohexane]-4-carbonitrile 1-oxide (X) and 5-oxo-3,5-dihydrospiro[benzimidazole-2,1'-cyclohexane]-4-carbonitrile 1-oxide (XI). Initially, cyanide ion is likely to react with I to give intermediate B, and next follows nucleophilic replacement of the nitro group by methoxy or hydroxy, as described in [11] for 5-nitrospiro-[benzimidazole-2,1'-cyclohexane]. Compound XI was formed as the only product when the reaction was carried out in a two-phase system (chloroform–water).

The structure of 5-methoxyspiro[benzimidazole-2,1'-cyclohexane]-4-carbonitrile 1-oxide (**X**) was determined on the basis of analytical and spectral data. The IR spectrum of **X** contained an absorption band at 2228 cm⁻¹, which is typical of stretching vibrations of






VII, Ar = Ph (a), 2-MeOC₆H₄ (b), 4-MeOC₆H₄ (c), 4-O₂NC₆H₄ (d), 4-H₂NSO₂ (e), 2-ClC₆H₄ (f); IX, Ar = Ph (a), 3-O₂NC₆H₄ (b), 4-MeOC₆H₄ (c).

cyano group. The other spectral parameters of X also confirmed the assumed structure. The structure of compound XI is likely to be similar to the structure of its known [11] analog having no N-oxide group. Compound XI displayed in the ¹³C NMR spectrum a signal at $\delta_{\rm C}$ 181.61 ppm, which is characteristic of quinoid carbonyl carbon atom. The position of the N-oxide group in XI was confirmed by its synthesis via reaction of VI with sodium cyanide (Scheme 2). The alkylation of XI with methyl iodide involved nitrogen atom in the imidazole ring with formation of compound XII. The IR spectrum of XII contained absorption bands at 2205 (C=N), 1541 (C=N), and 1616 cm⁻¹ (C=O). In the ¹H NMR spectrum of this compound, 10 protons in the cyclohexane ring resonated in the region δ 1.32–2.97 ppm, the *N*-methyl group gave

a three-proton singlet at δ 3.47 ppm, and two doublets at δ 6.40 and 7.44 ppm were assigned to 6-H and 7-H. In the ¹³C NMR spectrum of XII we observed three signals from methylene carbon atoms in the cyclohexane ring, and a signal at δ_C 31.43 ppm due to methyl carbon atom attached to nitrogen. The cyano group gave a signal at $\delta_{\rm C}$ 78.4 ppm, and two CH signals appeared at δ_C 120.35 and 131.01 ppm. The signal at $\delta_{\rm C}$ 95.35 ppm was assigned to the spiro carbon atom (C^2) , and the other quaternary carbon atoms resonated at 116.37, 131.84, and 154.12 ppm; the signal at $\delta_{\rm C}$ 181.75 ppm was typical of carbonyl carbon atom. These data in combination with the mass spectrum and elemental analysis allowed us to identify compound XII as 3-methyl-5-oxo-3,5-dihydrospiro[benzimidazole-2,1'-cyclohexane]-4-carbonitrile 1-oxide. In addi-



tion, a small amount of O-alkylation product **X** was isolated (Scheme 3).

The results of addition of nucleophilic reagents to 5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1,3-dioxide (I) were compared with the results of analogous reactions with 2*H*-benzimidazoles which are known to produce the corresponding 2,3-dihydro-1*H*-benzimidazoles [11–13] (Scheme 4). It may be presumed that addition of nucleophiles to 2*H*-benzimidazole 1,3-dioxide could give rise to 1,3-dihydroxy-2,3-dihydro-1*H*-benzimidazoles like C (Scheme 5). In fact, intermediate C loses water molecule, and the *ortho*-quinoid structure is retained. We believe that this is the main difference between 2*H*-benzimidazole 1,3-dioxides and 2*H*-benzimidazoles in reactions with nucleophiles.

EXPERIMENTAL

The IR spectra were recorded in KBr (sample concentration 0.25%) on a Bruker Vector-22 spectrometer; given are the most intense absorption bands. The UV spectra were measured on a Hewlett-Packard 4853 spectrophotometer from solutions in ethanol. The ¹H and ¹³C NMR spectra were obtained on a Bruker AV-300 instrument at 25°C from 10% solutions in $CDCl_3$ or DMSO- d_6 ; the chemical shifts were determined relative to the residual proton and carbon signals of the solvent (CHCl₃, δ 7.24, δ _C 76.90 ppm; DMSO- d_5 , δ 2.50, δ_C 39.50 ppm). Signal multiplicities in the ¹³C NMR spectra were determined using J-modulation (JMOD) technique. The mass spectra (electron impact, 70 eV) were recorded on a Thermo Scientific DFS mass spectrometer with direct sample admission into the ion source (ion source temperature 180°C); ion peaks with a relative intensity higher than 10% are given. The progress of reactions and the

purity of products were monitored by TLC on Sorbfil UV-254 plates (*Sorbpolimer*, Krasnodar, Russia); the chromatograms were developed under UV light and by treatment with iodine vapor. The melting points were measured on a Kofler hot stage. The elemental compositions were determined at the Microanalysis Laboratory, Novosibirsk Institute of Organic Chemistry, Siberian Division of the Russian Academy of Sciences. Compounds I [7] and VI [10] were synthesized by known methods.

Single crystals of compound **IIa** for X-ray analysis were obtained by recrystallization from ethyl acetatehexane (1:1). The X-ray diffraction data were acquired at 296 K on a Bruker KAPPA APEX II CCD diffractometer; $\lambda(MoK_{\alpha})$ 0.71073 Å, graphite monochromator, ω, φ -scanning, $2\theta < 50^{\circ}$. Crystallographic data for compound IIa: monoclinic crystal system, space group $P2_1/c$; unit cell parameters: a = 6.5118(3), b =22.2201(8), c = 8.4692(3) Å; $\beta = 101.814(2)^{\circ}$; V =1199.47(8) Å³; $C_{12}H_{14}N_4O_3$; Z = 4, $d_{calc} = 1.452$ g/cm³; $\mu = 0.108 \text{ cm}^{-1}$; crystal dimensions $0.06 \times 0.38 \times$ 0.40 mm. Absorption by the crystal was taken into account empirically using SADABS program $(T_{\min}/T_{\max} = 0.84/0.97)$. Intensities of 9846 reflections were measured, 2613 of which were independent $(R_{int} = 0.0483)$. The structure was solved by the direct method. The positions and temperature factors of nonhydrogen atoms were refined in anisotropic approximation by the full-matrix least-squares procedure. Hydrogen atoms in the amino group were localized by difference synthesis, while the other hydrogen atoms were placed into positions calculated on the basis of geometry considerations. The final divergence factors were $wR_2 = 0.1156$ (all reflections; S = 1.050), $R_1 =$ 0.0405 [2049 reflections with $I \ge 2\sigma(I)$]. All calculations were performed using SHELX and PLATON.

The crystallographic data for compound **IIa** were deposited to the Cambridge Crystallographic Data Centre (entry no. CCDC 827016).

5-Nitrospiro[benzimidazole-2,1'-cyclohexan]-4amine 1-oxide (IIa). Compound I, 1.32 g (0.005 mol), was dissolved in 60 ml of chloroform, 5 ml of a 25% solution of ammonia was added, and the mixture was stirred for 1 h at room temperature. The mixture was treated with 20 ml of water, the organic phase was separated, washed with water $(3 \times 20 \text{ ml})$, and dried over MgSO₄, the drying agent was filtered off, the filtrate was evaporated, the residue was dispersed in hexane, and the precipitate was filtered off. Yield 1.15 g (87%), mp 251–253°C. IR spectrum, v, cm⁻¹: 3451, 3331 (NH₂), 1632 (C=N). UV spectrum, λ_{max} , nm (logɛ): 350 (4.34), 500 (3.65). ¹H NMR spectrum (DMSO-d₆), δ, ppm: 1.25–2.04 m (10H, CH₂), 6.38 d (1H, CH, J = 10.0 Hz), 7.49 d (1H, CH, J = 10.0 Hz),8.87 br.s (2H, NH₂). ¹³C NMR spectrum, δ_C , ppm: 22.88, 24.21, 34.28 (CH₂); 101.50, 125.17 (CH); 106.23, 124.82, 134.13, 143.48, 159.07. Mass spectrum, m/z ($I_{\rm rel}$, %): 262 (100) $[M]^+$, 245 (48), 219 (80), 208 (61), 191 (42), 189 (46). Found, %: C 54.60; H 5.24; N 21.10. m/z 262.1068 $[M]^+$. C₁₂H₁₄N₄O₃. Calculated, %: C 54.95; H 5.38; N 21.37. M 262.1060.

N-Methyl-5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-amine 1-oxide (IIb). a. Compound IIb was synthesized as described above for IIa. Yield 76%, mp 228–230°C. IR spectrum, v, cm⁻¹: 3205 (NH), 1616 (C=N). UV spectrum, λ_{max} , nm (log ε): 229 (4.21), 363 (4.22), 401 (3.94), 527 (3.60). ¹H NMR spectrum, δ, ppm (CDCl₃): 1.23–2.18 m (10H, CH₂), 3.81 d (3H, CH₃, J = 6.0 Hz), 6.42 d (1H, CH, J =10.1 Hz), 7.63 d (1H, CH, J = 10.1 Hz), 10.55 br.s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 23.30, 24.46, 34.90 (CH₂); 34.69 (CH₃); 101.89, 125.86 (CH); 105.83, 126.31, 135.66, 145.03, 160.04. Mass spectrum, m/z ($I_{\rm rel}$, %): 276 (100) [M]⁺, 259 (41), 233 (80), 203 (56). Found, %: C 56.40; H 5.62; N 20.36. m/z 276.1220 $[M]^+$. C₁₃H₁₆N₄O₃. Calculated, %: C 56.51; H 5.84; N 20.28. M 276.1217.

b. Compound **IIa**, 0.3 g (0.0011 mol), was dissolved in 20 ml of acetonitrile, 0.5 g (0.0036 mol) of finely powdered calcined potassium carbonate and 2 ml (0.032 mol) of methyl iodide were added, and the mixture was stirred for 24 h at room temperature. The precipitate was filtered off, the solvent was removed, the residue was treated with 10 ml of water, and the precipitate was filtered off, washed with water, and dried. Yield 0.25 g (79%), mp 228–230°C.

2-[(5-Nitro-1-oxidospiro[benzimidazole-2,1'-cyclohexan]-4-yl)amino]ethanol (IIc). 2-Aminoethanol, 1.5 g (0.025 mol), was added to a solution of 5.26 g (0.02 mol) of compound I in 50 ml of chloroform, and the mixture was stirred for 1 h at room temperature. The solvent was distilled off under reduced pressure, and the residue was purified by chromatography on silica gel using chloroform-methanol (10:1) as eluent. Yield 86%, mp 195–197°C. IR spectrum, v, cm⁻¹: 3400 (NH), 1616 (C=N), 1450, 1329 (NO₂). UV spectrum, λ_{max} , nm (log ϵ): 230 (4.19), 360 (4.25), 520 (3.64). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.20–2.17 m (10H, CH₂), 2.24 br.s (1H, OH), 3.98-4.02 m (2H, CH₂), 4.46–4.51 m (2H, CH₂), 6.43 d (1H, CH, J =10.1 Hz), 7.63 d (1H, CH, J = 10.1 Hz), 10.67 s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 23.50, 24.45, 35.02, 48.54, 61.61 (CH₂); 102.05, 126.08 (CH); 105.72, 126.96, 135,98, 144.38, 160.12. Mass spectrum, m/z (I_{rel} , %): 306 (97) [M]⁺, 289 (15), 275 (100), 259 (58), 247 (56), 229 (37), 216 (39), 213 (34), 199 (32). Found, %: C 55.18; H 5.91; N 18.20. m/z 306.1328 $[M]^+$. C₁₄H₁₈N₄O₄. Calculated, %: C 54.89; H 5.92; N 18.29. M 306.1323.

Compounds **IId–IIm** were synthesized in a similar way.

5-Nitro-*N***-propylspiro**[**benzimidazole-2,1**′**-cyclohexan**]**-4-amine 1-oxide (IId).** Yield 76%, mp 198–201°C. IR spectrum, v, cm⁻¹: 2967 (NH), 1609 (C=N). UV spectrum, λ_{max} , nm (logε): 229 (4.17), 364 (4.16), 401 (3.83), 529 (3.57). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.04 t (3H, CH₃, *J* = 7.4 Hz), 1.23–2.17 m (12H, CH₂), 4.18–4.28 m (2H, CH₂), 6.41 d (1H, CH, *J* = 10.0 Hz), 7.63 d (1H, CH, *J* = 10.0 Hz), 10.61 s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 23.20, 23.34, 24.27, 34.70, 48.28 (CH₂); 10.94 (CH₃); 101.59, 125.75 (CH); 105.40, 126.08, 135.50, 144.29, 159.45. Mass spectrum, *m/z* (*I*_{rel}, %): 304 (100) [*M*]⁺, 287 (59), 275 (68), 247 (36), 241 (29). Found, %: C 58.95; H 6.60; N 18.46. *m/z* 304.1541 [*M*]⁺. C₁₅H₂₀N₄O₃. Calculated, %: C 59.19; H 6.62; N 18.41. *M* 304.1530

N-Butyl-5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-amine 1-oxide (IIe). Yield 78%, mp 162– 164°C. IR spectrum, v, cm⁻¹: 3236 (NH), 1604 (C=N). UV spectrum, λ_{max} , nm (logɛ): 231 (4.23), 364 (4.26), 401 (3.94), 529 (3.70). ¹H NMR spectrum (CDCl₃), δ, ppm: 0.90 t (3H, CH₃, *J* = 7.6 Hz), 1.20–2.17 m (14H, CH₂), 4.20–4.32 m (2H, CH₂), 6.37 d (1H, CH, *J* = 10.0 Hz), 7.59 d (1H, CH, *J* = 10.0 Hz), 10.60 s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 19.63, 23.12, 24.20, 31.94, 34.63, 46.40 (CH₂); 13.29 (CH₃); 101.47, 125.67 (CH); 105.32, 125.94, 135.44, 144.23, 159.39. Mass spectrum, m/z (I_{rel} , %): 318 (97) [M]⁺, 301 (62), 275 (100), 255 (29), 247 (41). Found, %: C 60.30; H 6.76; N 17.58. m/z 318.1688 [M]⁺. C₁₆H₂₂N₄O₃. Calculated, %: C 60.36; H 6.97; N 17.60. M 318.1686.

N-tert-Butyl-5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-amine 1-oxide (IIf). Yield 74%, mp 211– 213°C. IR spectrum, v, cm⁻¹: 2970 (NH), 1612 (C=N), 1427 (NO₂), 1226. UV spectrum, λ_{max} , nm (logɛ): 231 (4.22), 368 (4.27), 536 (3.72). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.20–2.18 m (10H, CH₂), 1.67 s (9H, CH₃), 6.41 d (1H, CH, *J* = 10.0 Hz), 7.65 d (1H, CH, *J* = 10.0 Hz), 11.23 s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 23.38, 24.24, 34.66 (CH₂); 29.61 (CH₃); 101.75, 136.02 (CH); 56.89, 105.00, 127.45, 135.94, 145.70, 157.92. Mass spectrum, *m/z* (*I*_{rel}, %): 318 (66) [*M*]⁺, 301 (5), 262 (81), 245 (62), 219 (100), 208 (93), 191 (39). Found, %: C 60.85; H 7.05; N 17.52. *m/z* 318.1685 [*M*]⁺. C₁₆H₂₂N₄O₃. Calculated, %: C 60.36; H 6.97; N 17.60. *M* 318.1686.

N-Cyclohexyl-5-nitrospiro[benzimidazole-2,1'cyclohexan]-4-amine 1-oxide (IIg). Yield 64%, mp 163–165°C. IR spectrum, v, cm⁻¹: 2928 (NH), 1605 (C=N), 1513, 1231 (NO₂). UV spectrum, λ_{max} , nm (log ε): 230 (4.14), 366 (4.20), 401 (3.87), 530 (3.66). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.20– 2.18 m (20H, CH₂), 5.10 m (1H, CH), 6.37 d (1H, CH, *J* = 10.0 Hz), 7.61 d (1H, CH, *J* = 10.0 Hz), 10.54 d (1H, NH, *J* = 7.8 Hz). ¹³C NMR spectrum, δ_{C} , ppm: 23.68, 24.51, 25.06, 33.59, 34.90 (CH₂); 54.77, 101.61, 126.07 (CH); 105.38, 126.01, 137.76, 143.53, 159.26. Mass spectrum, *m/z* (*I*_{rel}, %): 344 (66) [*M*]⁺, 327 (100), 309 (40), 301 (29). Found, %: C 63.0; H 6.96; N 16.54. *m/z* 344.1844 [*M*]⁺. C₁₈H₂₄N₄O₃. Calculated, %: C 62.77; H 7.02; N 16.27. *M* 344.18.43.

5-Nitro-N-(2,2,6,6-tetramethylpiperidin-4-yl)spiro[benzimidazole-2,1'-cyclohexan]-4-amine 1-oxide (IIh). Yield 72%, mp 217–220°C. IR spectrum: v 1607 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (log ϵ): 231 (4.29), 366 (4.33), 528 (3.83). ¹H NMR spectrum (CDCl₃), δ, ppm: 1.20–2.27 m (14H, CH₂), 1.15 s (6H, CH₃), 1.26 s (6H, CH₃), 5.28 m (1H, CH), 6.38 d (1H, CH, J = 10.0 Hz), 7.61 d (1H, CH, J = 10.0 Hz), 10.49 d (1H, NH, J = 8.0 Hz). ¹³C NMR spectrum, δ_{C} , ppm: 23.15, 24.26, 34.88, 45.81 (CH₂); 28.73, 34.60 (CH₃); 49.15, 101.69, 126.05 (CH); 50.53, 105.40, 126.32, 135.83, 143.40, 159.59. Mass spectrum, m/z $(I_{\rm rel}, \%)$: 401 (13) $[M]^+$, 138 (9), 124 (100). Found, %: C 63.0; H 7.70; N 17.30. m/z 401.2422 $[M]^+$. C₂₁H₃₁N₅O₃. Calculated, %: C 62.83; H 7.78; N 17.44. *M* 401.2421.

N-Benzyl-5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-amine 1-oxide (IIi). Yield 68%, mp 172-174°C. IR spectrum, v, cm⁻¹: 3247 (NH), 1609 (C=N). UV spectrum, λ_{max} , nm (log ϵ): 228 (4.21), 363 (4.22), 526 (3.64). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.22– 2.18 m (10H, CH₂), 5.55 d (2H, CH₂, J = 6.3 Hz), 7.38 s (5H, H_{arom}), 6.48 d (1H, CH, J = 10.0 Hz), 7.67 d (1H, CH, J = 10.0 Hz), 10.70 br.s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 23.02, 24.14, 34.66, 50.29 (CH₂); 102.05, 125.48, 127.04, 127.66, 128.57 (CH); 105.58, 127.03, 135.48, 136.65, 143.50, 159.45. Mass spectrum, m/z (I_{rel} , %): 352 (29) $[M]^+$, 335 (63), 317 (65), 307 (28), 287 (45), 105 (100). Found, %: C 64.73; H 5.69; N 16.08. m/z 352.1533 $[M]^+$. C₁₉H₂₀N₄O₃. Calculated, %: C 64.76; H 5.72; N 15.90. *M* 352.1533.

5-Nitro-N-(2-phenylethyl)spiro[benzimidazole-2,1'-cyclohexan]-4-amine 1-oxide (IIj). Yield 66%, mp 206–210°C. IR spectrum, v, cm⁻¹: 3199 (NH), 1615 (C=N). UV spectrum, λ_{max} , nm (log ε): 229 (4.13), 365 (4.15), 401 (3.79), 529 (3.60). ¹H NMR spectrum, δ, ppm (CDCl₃): 1.18–2.12 m (10H, CH₂), 3.03 t (2H, CH₂, J = 7.0 Hz), 4.54 g (2H, CH₂, J = 6.6, 14.6 Hz), 7.15-7.31 m (5H, Harom), 6.35 d (1H, CH, J = 10.3 Hz), 7.56 d (1H, CH, J = 10.3 Hz), 10.49 br.s (1H, NH). ¹³C NMR spectrum, $\delta_{\rm C}$, ppm: 23.13, 24.17, 34.66, 36.24, 47.66 (CH₂); 101.78, 125.63, 126.72, 128.34, 128.42 (CH); 105.39, 126.29, 134.46, 137.22, 143.98, 159.48. Mass spectrum, m/z (I_{rel} , %): 366 (46) $[M]^+$, 349 (60), 316 (25), 275 (95), 259 (54), 247 (38). m/z 366.1684 $[M]^+$. C₂₀H₂₂N₄O₃. Calculated, %: C 65.57; H 6.01; N 15.30. M 366.1686.

5-Nitro-4-piperidinospiro[benzimidazole-2,1'-cyclohexane] 1-oxide (IIk). Yield 48%, mp 159–162°C. IR spectrum: v 1596 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (log ε): 242 (4.11), 287 (3.75), 378 (3.91), 531 (3.70). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.23– 2.20 m (16H, CH₂), 3.51–3.70 m (4H, CH₂), 6.53 d (1H, CH, *J* = 9.8 Hz), 7.37 d (1H, CH, *J* = 9.8 Hz). ¹³C NMR spectrum, δ_{C} , ppm: 23.34, 23.25, 24.34, 25.94, 34.70, 52.80 (CH₂); 103.20, 126.87 (CH); 104.60, 132.68, 135.91, 142.38, 161.18. Mass spectrum, *m/z* (*I*_{rel}, %): 330 (54) [*M*]⁺, 313 (100), 287 (17), 274 (18), 257 (35). Found, %: C 61.68; H 6.66; N 16.87. *m/z* 330.1686 [*M*]⁺. C₁₇H₂₂N₄O₃. Calculated, %: C 61.80; H 6.75; N 16.96. *M* 330.1685

4-Morpholino-5-nitrospiro[benzimidazole-2,1'cyclohexane] 1-oxide (III). Yield 43%, mp 180– 182°C. IR spectrum: v 1591 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (log ϵ): 293 (3.64), 375 (3.79), 521 (3.62). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.15– 2.20 m (10H, CH₂), 3.55–3.70 m (4H, CH₂), 3.75– 3.90 m (4H, CH₂), 6.51 d (1H, CH, *J* = 10.0 Hz), 7.25 d (1H, CH, *J* = 10.0 Hz). ¹³C NMR spectrum, δ_{C} , ppm: 23.58, 24.52, 35.03, 51.70, 66.63 (CH₂); 104.80, 126.40 (CH); 105.25, 134.06, 136.08, 141.16, 161.43. Found, %: C 57.78; H 5.94; N 16.62. C₁₆H₂₀N₄O₄. Calculated, %: C 57.82; H 6.07; N 16.86.

5-Nitro-4-(pyrrolidin-1-yl)spiro[benzimidazole-2,1'-cyclohexane] 1-oxide (IIm). Yield 56%, mp 183– 188°C. IR spectrum: v 1594 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (log ε): 237 (4.24), 371 (4.01), 533 (3.76). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.10– 2.20 m (14H, CH₂), 3.79 s (4H, CH₂), 6.37 d (1H, CH, J = 10.0 Hz), 7.42 d (1H, CH, J = 10.0 Hz). ¹³C NMR spectrum, δ_{C} , ppm: 23.36, 24.59, 25.48, 34.88, 55.31 (CH₂); 100.99, 128.74 (CH); 104.66, 129.85, 136.16, 141.37, 160.66. Mass spectrum, m/z (I_{rel} , %): 316 (40) [M]⁺, 299 (100), 266 (48), 265 (58), 253 (47), 243 (80), 225 (47). Found, %: C 60.32; H 6.37; N 17.66. m/z 316.1523 [M]⁺. C₁₆H₂₀N₄O₄. Calculated, %: C 60.76; H 6.33; N 17.72. M 316.1530.

5-Nitrospiro[benzimidazole-2,1'-cyclohexan]-4-ol 1-oxide (III). *a*. Compound I, 2.63 g (0.01 mol), was added to a solution of 0.7 g (0.017 mol) of sodium hydroxide in 100 ml of water, and the mixture was vigorously stirred for 6 h at room temperature. The solvent was distilled off to a volume of 20 ml, 5% hydrochloric acid was added until pH 3, and the precipitate was filtered off, washed with water, and dried. The crude product, 2.25 g, was dissolved in alcohol and subjected to chromatography on silica gel using ethyl acetate–hexane (3:1 + 1%) of methanol) as eluent. Yield 1.99 g (76%).

b. A solution of 0.5 g (0.0125 mol) of sodium hydroxide in 5 ml of water was added to a solution of 1.0 g (0.00386 mol) of compound IIa in 50 ml of methanol, and the mixture was heated for 30 min under reflux. The solvent was distilled off under reduced pressure (water-jet pump), 10 ml of water was added to the residue, and the mixture was acidified to pH 3 with 5% hydrochloric acid. The precipitate was filtered off, washed with water, and dried. Yield 0.83 g (82%), mp 165°C (decomp.). IR spectrum: v 1606 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (log ϵ): 227 (4.11), 282 (3.45), 349 (3.98), 403 (4.02), 509 (3.34). ¹H NMR spectrum (DMSO- d_6), δ , ppm: 1.23–1.98 m (10H, CH₂), 6.58 d (1H, CH, J = 10.0 Hz), 7.40 d (1H, CH, J = 10.0 Hz), 9.43 br.s (1H, OH). ¹³C NMR spectrum, δ_C, ppm: 22.83, 24.21, 34.34 (CH₂); 103.90, 125.52

(CH); 105.80, 133.18, 135.75, 153.24, 160.21. Mass spectrum: m/z (I_{rel} , %): 263 (45) [M]⁺, 247 (100), 229 (23), 212 (46). Found, %: C 54.62; H 4.96, N 16.10. m/z 263.0902 [M]⁺. C₁₂H₁₃N₃O₄. Calculated, %: C 54.75; H 4.98; N 15.96. M 263.0901.

Following a similar procedure, compound III was obtained from compounds IIc, IIk, and III in 95, 72, and 84% yield, respectively.

4-Methoxy-5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1-oxide (IV). A solution of diazomethane prepared from 1 g of nitrosomethylurea in 50 ml of ether was added dropwise at room temperature to a solution of 1.0 g (0.038 mol) of compound III in 25 ml of methanol. The mixture was stirred for 2 h at 20°C, the solvent was distilled off under reduced pressure, and the residue was purified by chromatography on silica gel using ethyl acetate-hexane (1:3) as eluent. Yield 0.38 g (36%), mp 75-78°C. IR spectrum: v 1600 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (log ϵ): 281 (3.78), 322 (3.76), 447 (3.64). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.19–1.98 m (10H, CH₂), 4.48 s (3H, OCH_3), 6.86 d (1H, CH, J = 9.2 Hz), 7.06 d (1H, CH, J = 9.2 Hz). ¹³C NMR spectrum, $\delta_{\rm C}$, ppm: 23.06, 24.18, 34.88 (CH₂); 62.08 (OCH₃); 109.44, 123.36 (CH); 106.70, 135.83, 140.02, 148.21, 158.16. Mass spectrum: m/z (I_{rel} , %): 277 (100) $[M]^+$, 260 (55), 247 (43), 223 (36), 213 (31), 206 (86). Found, %: C 56.82; H 5.60; N 15.05. m/z 277.1051 $[M]^+$. C₁₃H₁₅N₃O₄. Calculated, %: C 56.31; H 5.45; N 15.16. M 277.1057.

5-Nitrospiro[benzimidazole-2,1'-cyclohexan]-4amine 1,3-dioxide (Va). Manganese(IV) oxide, 10 g, was added to a solution of 2.63 g (0.01 mol) of compound I in 100 ml of chloroform, and dry ammonia was passed through the mixture over a period of 2 h under vigorous stirring at room temperature. The precipitate was filtered off, the solvent was distilled off under reduced pressure, and the residue was subjected to chromatography on silica gel using chloroform as eluent to isolate 0.45 g (17%) of N-oxide IIa and 1.20 g (44%) of N,N-dioxide Va. mp 215-217°C. IR spectrum, v, cm⁻¹: 3362, 3252 (NH₂); 1617 (C=N). UV spectrum, λ_{max} , nm (log ϵ): 265 (4.03), 335 (3.98), 621 (3.38). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.53– 2.09 m (10H, CH_2), 6.47 d (1H, CH, J = 10.1 Hz), 7.58 d (1H, CH, J = 10.1 Hz), 8.75 br.s (1H, NH), 9.22 br.s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 18.62, 22.86, 33.70 (CH₂); 101.06, 126.76 (CH); 99.82, 123.64, 130.35, 134.61, 140.16. Mass spectrum, m/z ($I_{\rm rel}$, %): 278 (100) $[M]^+$, 262 (52), 207 (47), 180 (44). Found, %: C 52.11; H 5.12; N 20.20.

m/z 278.1008 $[M]^+$. C₁₂H₁₄N₄O₄. Calculated, %: C 51.80; H 5.04; N 20.14. *M* 278.1010.

N-Methyl-5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-amine 1,3-dioxide (Vb) was synthesized in a similar way. Yield 61%, mp 135–137°C. IR spectrum: v 1592 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (logε): 267 (4.18), 366 (4.00), 589 (3.48). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.28–2.04 m (10H, CH₂), 2.95 d (3H, CH₃, *J* = 5.8 Hz), 6.39 d (1H, CH, *J* = 10.0 Hz), 7.38 d (1H, CH, *J* = 10.0 Hz), 9.50 br.s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 18.64, 23.04, 33.45 (CH₂); 33.78 (CH₃); 101.65, 129.37 (CH); 100.04, 125.80, 131.63, 134.91, 139.90. Mass spectrum, *m/z* (*I*_{rel}, %): 292 (4) [*M*]⁺, 276 (17), 183 (100), 153 (63). Found, %: C 53.38; H 5.35; N 18.85. *m/z* 292.1172 [*M*]⁺. C₁₃H₁₆N₄O₄. Calculated, %: C 53.42; H 5.52; N 19.17. *M* 292.1166.

5-Nitro-N-phenylspiro[benzimidazole-2,1'-cyclohexan]-4-amine (VIIa). Aniline, 2.0 g (0.02 mol), was added to a solution of 2.63 g (0.01 mol) of compound I in 80 ml of benzene, and the mixture was heated for 6 h under reflux. The solvent was distilled off, and the residue was purified by chromatography on silica gel using ethyl acetate-hexane (1:3) as eluent. Yield 1.70 g (55%), mp 187–190°C. IR spectrum, v, cm⁻¹: 3194 (NH), 1631 (C=N). UV spectrum, λ_{max} , nm (log ϵ): 248 (4.13), 360 (4.06), 500 (3.75). ¹H NMR spectrum (CDCl₃), δ, ppm: 0.95–1.94 m (10H, CH₂), 6.60 d (1H, CH, J = 10.1 Hz), 7.91 d (1H, CH, J = 10.1 Hz), 7.17– 7.24 m (2H, H_{arom}), 7.29–7.39 m (3H, H_{arom}), 11.49 s (1H, NH). ¹³C NMR spectrum, $\delta_{\rm C}$, ppm: 23.77, 24.95, 32.76 (CH₂); 112.05, 131.69, 125.43, 127.10, 128.33 (CH); 109.45, 129.89, 137.85, 142.39, 154.35, 161.05. Mass spectrum, m/z (I_{rel} , %): 322 (100) $[M]^+$, 305 (27), 287 (30), 275 (32). Found, %: C 67.37; H 5.51; N 17.11. m/z 322.1347 $[M]^+$. C₁₈H₁₇N₄O₂. Calculated, %: C 67.20; H 5.60; N 17.30. M 322.1424.

Compounds **VIIb–VIIf** were synthesized in a similar way.

N-(2-Methoxyphenyl)-5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-amine (VIIb). Yield 41%, mp 172–174°C. IR spectrum, v, cm⁻¹: 3425 (NH), 1633 (C=N). UV spectrum, λ_{max} , nm (log ε): 252 (4.03), 272 (4.06), 361 (4.00), 500 (3.68). ¹H NMR spectrum (CDCl₃), δ, ppm: 0.78–1.90 m (10H, CH₂), 3.68 s (3H, OCH₃), 6.55 d (1H, CH, *J* = 10.2 Hz), 7.90 d (1H, CH, *J* = 10.2 Hz), 6.88–6.96 m (2H, CH), 7.16–7.30 m (2H, CH), 11.30 s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 23.78, 24.91, 32.74 (CH₂); 54.86 (OCH₃); 110.49, 111.54, 119.84, 125.90, 128.24, 131.98 (CH); 109.08, 125.48, 126.80, 143.08, 153,40, 154.68, 158.13. Mass spectrum, m/z (I_{rel} , %): 352 (21) $[M]^+$, 337 (25), 321 (100), 304 (12). Found, %: C 64.70; H 5.68; N 15.85. m/z 352.1531 $[M]^+$. C₁₉H₂₀N₄O₃. Calculated, %: C 64.76; H 5.72; N 15.90. *M* 352.1530.

N-(4-Methoxyphenyl)-5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-amine (VIIc). Yield 35%, mp 153–155°C. IR spectrum, v, cm⁻¹: 3204 (NH), 1631 (C=N). UV spectrum, λ_{max} , nm (log ε): 225 (4.25), 361 (4.04), 502 (3.70). ¹H NMR spectrum (CDCl₃), δ, ppm: 1.09–1.88 m (10H, CH₂), 3.84 s (3H, OCH_3), 6.59 d (1H, CH, J = 10.3 Hz), 7.94 d (1H, CH, J = 10.3 Hz), 6.88 d (2H, H_{arom}, J = 8.9 Hz), 7.14 d (2H, H_{arom}, J = 8.9 Hz), 11.56 s (1H, NH). ¹³C NMR spectrum, δ_C, ppm: 24.06, 25.25, 33.05 (CH₂); 55.48 (OCH₃); 111.92, 113.85, 126.90, 132.22 (CH); 109.63, 125.80, 130.98, 143.24, 154,73, 158.52, 158.86. Mass spectrum, m/z (I_{rel} , %): 352 (100) [M]⁺, 337 (67), 318 (24), 290 (17). Found, %: C 64.85; H 5.65; N 16.10. m/z 352.1527 $[M]^+$. C₁₉H₂₀N₄O₃. Calculated, %: C 64.76; H 5.72; N 15.90. M 352.1530.

5-Nitro-*N***-(4-nitrophenyl)spiro[benzimidazole-2,1'-cyclohexan]-4-amine (VIId).** Yield 70%, mp 108–110°C. IR spectrum: v 1636 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (logɛ): 268 (4.15), 344 (4.13), 494 (3.88). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.20–1.85 m (10H, CH₂), 6.76 d (1H, CH, *J* = 10.1 Hz), 7.32 d (2H, H_{arom}, *J* = 9.0 Hz), 7.87 d (1H, CH, *J* = 10.1 Hz), 8.19 d (2H, H_{arom}, *J* = 9.0 Hz), 11.07 s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 23.90, 24.77, 32.46 (CH₂); 114.43, 123.72, 125.00, 130.84 (CH); 110.11, 128.84, 139.50, 143.78, 145.28, 154.11, 157.94. Mass spectrum, *m/z* (*I*_{rel}, %): 367 (61) [*M*]⁺, 350 (100), 332 (22), 320 (47). Found, %: C 58.92; H 5.09; N 19.21. *m/z* 367.1267 [*M*]⁺. C₁₈H₁₇N₅O₄. Calculated, %: C 58.85; H 4.66; N 19.07. *M* 367.1275.

4-[(5-Nitro-1-oxidospiro[benzimidazole-2,1'-cyclohexan]-4-yl)amino]benzenesulfonamide (VIIe). Yield 36%, mp 182–185°C. IR spectrum: v 1634 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (log ϵ): 268 (3.98), 358 (3.74), 500 (3.56). ¹H NMR spectrum (DMSO-*d*₆), δ , ppm: 1.30–1.87 m (10H, CH₂), 6.77 d (1H, CH, *J* = 9.9 Hz), 7.35–7.42 m (4H, H_{arom}, NH₂), 7.69–7.81 m (3H, H_{arom}), 11.05 s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 23.96, 24.92, 32.46 (CH₂); 113.48, 123.52, 125.84, 132.34 (CH); 109.01, 128.39, 138.89, 140.67, 142.53, 155.99, 158.34. Mass spectrum, *m/z* (*I*_{rel}, %): 401 (68) [*M*]⁺, 366 (77), 338 (17), 303 (20), 274 (100). Found, %: C 54.05; H 4.70; N 17.20; S 8.10.

RUSSIAN JOURNAL OF ORGANIC CHEMISTRY Vol. 48 No. 3 2012

m/z 401.1158 $[M]^+$. C₁₈H₁₉N₅O₄S. Calculated, %: C 53.87; H 4.74; N 17.46; S 7.98. *M* 401.1152.

N-(2-Chlorophenyl)-5-nitrospiro[benzimidazole-2,1'-cyclohexan]-4-amine (VIIf). Yield 52%, mp 192–195°C. IR spectrum: v 1633 cm⁻¹ (C=N). UV spectrum, λ_{max}, nm (logε): 255 (4.13), 352 (4.06), 488 (3.73). ¹H NMR spectrum (CDCl₃), δ , ppm: 0.93– 1.97 m (10H, CH₂), 6.62 d (1H, CH, J = 10.1 Hz), 7.23-7.33 m (3H, H_{arom}), 7.38-7.44 m (1H, H_{arom}), 7.91 d (1H, CH, J = 10.1 Hz), 11.22 s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 23.76, 24.87, 32.63 (CH₂); 112.51, 126.77, 127.56, 128.40, 129.33, 131.46 (CH); 109.58, 125.98, 131.00, 135.75, 142.32, 154.36, 157.88. Mass spectrum, m/z (I_{rel} , %): 356 (33) [M]⁺, 321 (100), 304 (32), 274 (29). Found, %: C 61.1; H 4.70; Cl 10.4; N 20.11. m/z 356.1036 $[M]^+$. C₁₈H₁₇ClN₄O₂. Calculated, %: C 60.67; H 4.78; Cl 9.97; N 19.93. M 356.1035.

5-Azidospiro[benzimidazole-2,1'-cyclohexane]-**1,3-dioxide (VIII).** Sodium azide, 0.80 g (0.012 mol), was added to a solution of 2.63 g (0.01 mol) of compound I in 80 ml of methanol, and the mixture was stirred for 24 h at room temperature. The solvent was distilled off under reduced pressure, the residue was extracted with chloroform, the extract was dried over MgSO₄, the drying agent was filtered off, the solvent was distilled off, and the residue was purified by chromatography on silica gel using chloroform as eluent. Yield 1.0 g (38%), mp 83°C (decomp.) IR spectrum, v, cm⁻¹: 2117 (N₃), 1589 (C=N). UV spectrum, λ_{max} , nm (logε): 266 (4.37), 292 (4.36), 543 (3.66). ¹Η NMR spectrum (CDCl₃), δ, ppm: 1.39–2.04 m (10H, CH₂), 6.48 d.d (1H, CH, J = 9.8, 1.8 Hz), 6.80 d (1H, CH, J = 1.8 Hz), 7.19 d (1H, CH, J = 9.8 Hz). ¹³C NMR spectrum, δ_C, ppm: 18.65, 23.06, 33.27 (CH₂); 101.25, 116.80, 123.43 (CH); 97.75, 134.33, 135.40, 142.55. Found, %: C 55.10; H 4.90; N 26.88. C₁₂H₁₃N₅O₂. Calculated, %: C 55.59; H 5.05; N 27.02.

N-Phenylspiro[benzimidazole-2,1'-cyclohexan]-5-amine 1-oxide (IXa). Aniline hydrochloride, 1.3 g (0.01 mol), was added to a solution of 2.63 g (0.01 mol) of compound I in 80 ml of methanol, and the mixture was heated for 4 h under reflux. The solvent was distilled off, 30 ml of water was added to the residue, and the mixture was adjusted to pH 8 by adding a 10% solution of sodium hydroxide and extracted with chloroform (3×20 ml), The extract was dried over MgSO₄, the drying agent was filtered off, the solvent was distilled off, and the residue was subjected to chromatography on aluminum oxide using chloroform as eluent to isolate compounds IXa (first fraction) and IXd (second fraction). Compound IXa: Yield 1.65 g (56%), mp 168–170°C. IR spectrum: v 1623 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (log ϵ): 249 (4.31), 369 (4.46), 511 (3.63). ¹H NMR spectrum, δ, ppm: in CDCl₃: 1.20-2.10 m (10H, CH₂), 6.43 d (1H, CH, J = 0.8 Hz), 6.57 d.d (1H, CH, J = 9.6, 1.5 Hz), 7.08-7.20 m (4H, H_{arom}), 7.28-7.35 m (2H, H_{arom}); in DMSO-d₆: 0.81–2.14 m (10H, CH₂), 6.28 s (1H, 4-H), 6.77 d.d (1H, 6-H, J = 9.8, J = 1.4 Hz), 7.17 d (1H, 7-H, J = 9.8 Hz, 7.06–7.17 m (1H, H_{arom}), 7.24–7.31 m (2H, H_{arom}), 7.35-7.44 m (2H, H_{arom}), 8.96 br.s (1H, NH). ¹³C NMR spectrum (CDCl₃), $\delta_{\rm C}$, ppm: 23.52, 24.78, 35.05 (CH₂); 94.87, 117.52, 122.48, 124.62, 127.52, 129.34 (CH); 104.74, 132.64, 139.07, 148.88, 161.82. Mass spectrum: m/z (I_{rel} , %): 293 (88) [M]⁺, 277 (100), 264 (45), 250 (52). Found, %: C 73.49; H 6.48; N 14.34. m/z 293.1521 $[M]^+$. C₁₈H₁₉N₃O. Calculated, %: C 73.69; H 6.53; N 14.33. M 293.1523.

N-Phenylspiro[benzimidazole-2,1'-cyclohexan]-5-amine 1,3-dioxide (IXd). Yield 0.15 g (5%), dark green crystals, mp 142–145°C. IR spectrum, v, cm^{-1} : 3268 (NH), 1595 (C=N). UV spectrum, λ_{max} , nm $(\log \epsilon)$: 257 (4.48), 279 (4.72), 413 (4.38), 620 (3.5). ¹H NMR spectrum (CDCl₃), δ , ppm: 1.48–2.06 m $(10H, CH_2), 6.43 d (1H, CH, J = 1.6 Hz), 6.74 d.d (1H, CH_2), 6.74 d.$ CH, J = 9.9, 1.6 Hz), 7.04–7.13 m (4H, H_{arom}), 7.22– 7.28 m (2H, H_{arom}), 7.34 br.s (1H, NH). ¹³C NMR spectrum, δ_C, ppm: 19.45, 23.63, 33.62 (CH₂); 87.25, 116.24, 122.30, 124.67, 129.05, 129.44 (CH); 96.83, 134.09, 136.95, 138.98, 146.18. Mass spectrum, m/z $(I_{\rm rel}, \%)$: 309 (37) $[M]^+$, 293 (63), 277 (100), 276 (65), 264 (23), 250 (22), 222 (55), 213 (35), 181 (20), 167 (35), 154 (42). Found, %: C 70.49; H 6.48; N 13.34. m/z 309.1472 $[M]^+$. C₁₈H₁₉N₃O₂. Calculated, %: C 69.90; H 6.14; N 13.59. M 309.1471.

N-(3-Nitrophenyl)spiro[benzimidazole-2,1'-cyclohexan]-5-amine 1-oxide (IXb) was synthesized in a similar way. Yield 51%, mp 186–189°C. IR spectrum, v, cm⁻¹: 3327 (NH), 1598 (C=N). UV spectrum, λ_{max} , nm (log ε): 368 (4.18), 486 (3.78). ¹H NMR spectrum, δ , ppm: in CDCl₃: 1.24–2.13 m (10H, CH₂), 6.56 s (1H, 4-H), 6.62 d.d (1H, CH, *J* = 10.0, 1.5 Hz), 7.22 d (1H, 7-H, *J* = 10.0 Hz), 7.50 t (1H, H_{arom}, *J* = 8.0 Hz), 7.57 d (1H, H_{arom}, *J* = 8.0 Hz), 7.93 d (1H, H_{arom}, *J* = 8.0 Hz), 8.01 s (1H, H_{arom}); in DMSO-*d*₆: 1.10–1.90 m (10H, CH₂), 6.53 br.s (1H, 4-H), 6.77 d.d (1H, 6-H, *J* = 10.0, 2.0 Hz), 7.22 d (1H, 7-H, *J* = 10.0, Hz), 7.70 d (1H, H_{arom}, *J* = 8.0 Hz), 7.87 d (1H, H_{arom}, *J* = 8.0 Hz), 8.01 br.s (1H, H_{arom}), 9.37 br.s (1H, NH). ¹³C NMR

spectrum (CDCl₃), $\delta_{\rm C}$, ppm: 23.46, 24.58, 35.08 (CH₂); 97.11, 116.04, 118.08, 118.56, 126.96, 130.21 (CH); 105.02, 132.73, 140.96, 147.89, 148. 96, 161.36. Mass spectrum, *m/z* (*I*_{rel}, %): 338 (40) [*M*]⁺, 322 (100), 320 (42), 309 (16), 295 (19), 276 (27), 275 (22), 274 (18), 255 (13) 221 (25). Found, %: C 63.25; H 5.10; N 16.34. *m/z* 338.1369 [*M*]⁺. C₁₈H₁₈N₄O₃. Calculated, %: C 63.90; H 5.32; N 16.57. *M* 338.1373.

N-(4-Methoxyphenyl)spiro[benzimidazole-2,1'cyclohexan]-5-amine 1-oxide (IXc). Yield 41%, mp 193–195°C. IR spectrum: v 1619 cm⁻¹ (C=N). UV spectrum, λ_{max} , nm (log ϵ): 251 (4.12), 369 (4.02), 507 (3.38). ¹H NMR spectrum, δ, ppm: in CDCl₃: 1.17– 2.08 m (10H, CH₂), 3.77 s (3H, OCH₃), 6.18 d (1H, 4-H, J = 1.5 Hz), 6.51 d.d (1H, 6-H, J = 9.8, 1.5 Hz), 6.84 d (2H, H_{arom}, J = 8.9 Hz), 7.11 d (2H, H_{arom}, J =8.9 Hz), 7.12 d (1H, 7-H, J = 9.8 Hz); in DMSO- d_6 : 0.92-1.95 m (10H, CH₂), 3.76 s (3H, OCH₃), 6.01 s (1H, 4-H), 6.73 d.d (1H, 6-H, J = 9.6, 1.8 Hz), 6.97 d $(2H, H_{arom}, J = 9.0 \text{ Hz}), 7.14 \text{ d} (1H, H_{arom}, J = 9.6 \text{ Hz}),$ 7.20 d (2H, H_{arom} , J = 9.0 Hz), 8.77 br.s (1H, NH). ¹³C NMR spectrum (CDCl₃), $δ_C$, ppm: 23.49, 24.66, 35.07 (CH₂); 93.57, 114.56, 117.53, 125.44, 127.22 (CH); 65.42 (OCH₃); 104.46, 131.54, 132.60, 150.29, 157.25, 161.63. Mass spectrum, m/z (I_{rel} , %): 323 (100) $[M-32]^+$, 307 (98), 292 (97), 290 (16), 280 (56), 265 (15). Found, %: C 64.00; H 6.12; N 11.34. m/z 323.1682 $[M - 32]^+$. C₁₉H₂₁N₃O₄. Calculated, %: C 64.22; H 5.91; N 11.83. M 355.1629.

5-Methoxyspiro[benzimidazole-2,1'-cyclohexane]-4-carbonitrile 1-oxide (X) and 5-oxo-3,5-dihydrospiro[benzimidazole-2,1'-cyclohexane]-4-carbonitrile 1-oxide (XI). a. Sodium cyanide, 0.70 g (0.014 mol), was added to a solution of 2.63 g (0.01 mol) of compound I in 40 ml of methanol, and the mixture was stirred for 4 h at room temperature. The solvent was distilled off under reduced pressure, 40 ml of water was added to the residue, and the mixture was acidified to pH 3 with 5% hydrochloric acid and extracted with ethyl acetate. The extract was washed with a saturated solution of sodium chloride and dried over MgSO₄, the drying agent was filtered off, the solvent was distilled off, and the residue was subjected to chromatography on silica gel using chloroform-methanol (10:1) as eluent to isolate compounds X (first fraction) and XI. Compound X: Yield $0.60 \text{ g} (23\%), \text{ mp } 193-196^{\circ}\text{C}. \text{ IR spectrum, } v, \text{ cm}^{-1}$: 2228 (CN), 1600 (C=N). UV spectrum, λ_{max} , nm (logε): 224 (4.44), 352 (4.00), 465 (3.45). ¹H NMR spectrum (CDCl₃), δ, ppm: 1.17–2.00 m (10H, CH₂), 4.15 s (3H, OCH₃), 6.72 d (1H, CH, J = 9.0 Hz), 7.39 d (1H, CH, J = 9.0 Hz). ¹³C NMR spectrum, $\delta_{\rm C}$, ppm: 22.94, 24.28, 34.93 (CH₂); 57.76 (OCH₃); 119.24, 122.07 (CH); 92.44, 104.44, 112.71, 131.55, 158.27, 169.23. Mass spectrum, m/z ($I_{\rm rel}$, %): 257 (100) [M]⁺, 240 (58), 228 (49), 212 (20). Found, %: C 65.66; H 5.77; N 16.31. m/z 257.1161 [M]⁺. C₁₄H₁₅N₃O₂. Calculated, %: C 65.35; H 5.88; N 16.33. M 257.1159.

Compound **XI**. Yield 0.50 g (20%), mp 241–242°C. IR spectrum, v, cm⁻¹: 2226, 2213 (CN); 1630, 1615, 1538 (C=O, C=N). UV spectrum, λ_{max} , nm (logɛ): 249 (3.88), 345 (4.20), 438 (3.41). ¹H NMR spectrum (DMSO-*d*₆), δ , ppm: 0.96–1.98 m (10H, CH₂), 6.35 d (1H, CH, *J* = 9.8 Hz), 7.41 d (1H, CH, *J* = 9.8 Hz), 11.18 br.s (1H, NH). ¹³C NMR spectrum, δ_{C} , ppm: 21.39, 23.90, 35.02 (CH₂); 120.67, 131.82 (CH); 79.35, 96.32, 115.73, 131.52, 156.91, 181.61. Mass spectrum, *m*/*z* (*I*_{rel}, %): 243 (100) [*M*]⁺, 226 (70), 214 (23), 200 (32). Found, %: C 63.93; H 5.23; N 16.85. *m*/*z* 243.1002 [*M*]⁺. C₁₃H₁₃N₃O₂. Calculated, %: C 64.18; H 5.39; N 17.28. *M* 243.1006.

b. A solution of 0.70 g (0.014 mol) of sodium cyanide in 10 ml of water was added to a solution of 2.63 g (0.01 mol) of compound I in 80 ml of chloroform. The mixture was vigorously stirred for 4 h at room temperature, 20 ml of water was added, and the organic phase was separated and washed with water (2×10 ml). The aqueous phase was acidified to pH 3 with 5% hydrochloric acid and extracted with chloroform (3×50 ml), the extract was dried over MgSO₄, the drying agent was filtered off, the solvent was distilled off, and the residue was purified by chromatography on silica gel using chloroform–methanol (10:1) as eluent. Yield of **XI** 1.84 g (71%).

3-Methyl-5-oxo-3,5-dihydrospiro[benzimidazole-2,1'-cvclohexane]-4-carbonitrile 1-oxide (XII). Compound XI, 1.0 g (0.0041 mol), was dissolved in 80 ml of acetone, 11.35 g (0.008 mol) of methyl iodide and 3.0 g (0.02 mol) of calcined potassium carbonate were added, and the mixture was stirred for 16 h at room temperature. The precipitate was filtered off, the solvent was distilled off from the filtrate, and the residue was subjected to chromatography on silica gel using chloroform as eluent to isolate 0.08 g (8%) of methoxy derivative X and 0.87 g (82%) of compound XII, mp 256°C (decomp.). IR spectrum, v, cm^{-1} : 2204 (CN), 1616 (C=N). UV spectrum, λ_{max} , nm (log ϵ): 234 (3.30), 259 (3.18), 270 (3.10), 351 (3.70), 447 (3.00). ¹H NMR spectrum (DMSO- d_6), δ , ppm: 1.20–2.17 m (10H, CH₂), 3.47 s (3H, CH₃), 6.40 d (1H, CH, J= 10.0 Hz), 7.44 d (1H, CH, J = 10.0 Hz). ¹³C NMR spectrum, $\delta_{\rm C}$, ppm: 19.30, 22.64, 31.43 (CH₂); 30.04 (CH₃); 120.35, 131.01 (CH); 78.40, 95.53, 116.37, 131.84, 154.12, 181.75. Mass spectrum, *m/z* (*I*_{rel}, %): 257 (65.6) [*M*]⁺, 241 (82.3), 240 (40.6), 198 (82), 186 (100). Found, %: C 64.97; H 5.60; N 16.30. *m/z* 257.1162 [*M*]⁺. C₁₄H₁₅N₃O₂. Calculated, %: C 65.35; H 5.88; N 16.33. *M* 257.1159.

Reactions of 5-nitrospiro[benzimidazole-2,1'-cyclohexane] 1-oxide (VI) with nucleophilic reagents. The conditions for the reactions of compound VI with 2-aminoethanol, morpholine, piperidine, 3-nitroaniline hydrochloride, and sodium cyanide were the same as in the corresponding reactions with compound I. The yields of **IIc**, **IIk**, **III**, **IXb**, and **XI** were 48, 18, 49, 15, and 17%, respectively.

REFERENCES

- 1. Suschitzky, H., Croat. Chim. Acta, 1986, vol. 59, p. 57.
- 2. Brian, I., Bull. Soc. Chim. Belg., 1990, vol. 99, p. 673.
- Latham, D.W.S., Meth-Cohn, O., Suschitzky, H., and Herbert, J.A.L., J. Chem. Soc., Perkin Trans. 1, 1977, p. 470.
- Boiani, M., Boiani, L., Denicola, A., Torres de Ortiz, S., Serna, E., Bilbao, N.V., Sanabria, L., Yaluff, G., Nakaya-

ma, H., Arias, A.R., Vega, C., Rolan, M., Gomez-Barrio, A., Cerecetto, H., and Gonzalez, M., *J. Med. Chem.*, 2006, vol. 49, p. 3215.

- Boiani, M., Boiani, L., Merlino, A., Hernandez, P., Chidichimo, A., Cazzulo, J.J., Cerecetto, H., and Gonzalez, M., *Eur. J. Med. Chem.*, 2009, vol. 44, p. 4426.
- Merlino, A., Benitez, D., Chavez, S., Da Cunha, J., Hernandez, P., Tinoco, L.W., Campillo, N.E., Paez, J.A., Cerecetto, H., and Gonzalez, M., *Med. Chem. Commun.*, 2010, vol. 1, p. 216.
- Samsonov, V.A., Volodarskii, L.B., and Shamirzaeva, O.V., *Khim. Geterotsikl. Soedin.*, 1994, p. 524.
- Samsonov, V.A. and Volodarskii, L.B., *Zh. Org. Khim.*, 1982, vol. 18, p. 656.
- Kafluoroy, M., Shteiman, V., and Botoshansky, M., Acta Crystallogr., Sect. C, 2002, vol. 58, p. o183.
- Samsonov, V.A., Bagryanskaya, I.Yu., Gatilov, Yu.V., and Savel'ev, V.A., *Izv. Ross. Akad. Nauk, Ser. Khim.*, 2011, p. 1697.
- 11. Cada, A., Kramer, W., Neidlein, R., and Suschitzky, H., Helv. Chim. Acta, 1990, vol. 73, p. 902.
- Davies, K.E., Domany, G.E., Farhat, M., Herbert, J.A.L., Jefferson, A.M., Martin, M.A.G., and Suschitzky, H., *J. Chem. Soc., Perkin Trans. 1*, 1984, p. 2465.
- Gorelik, M.V. and Gladysheva, T.Kh., *Zh. Org. Khim.*, 1977, vol. 13, p. 1958.